Skip to main content

LCD L40378: Urine-based Biomarkers in Patients with Microhematuria

LCD L40378, Urine-based Biomarkers in Patients with Microhematuria, is the Local Coverage Determination that Novitas Solutions, Inc. applies to claims from 11 states plus DC (AR, CO, DC, DE, LA, MD, MS, NJ and others), effective 2026-12-20. The policy text runs 764 words, and its billing and coding article A60424 lists 3 ICD-10-CM codes that support medical necessity for 13 procedure codes. 1 other contractor version share this title, so the criteria depend on where the service is furnished. Counting every linked billing and coding article, this one lists 3 covered ICD-10-CM codes: the same total as L40380 (First Coast Service Options, Inc., 3 codes, revised 2026-12-20).

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: Medicare Coverage Database LCD export: MCD release November 12, 2026 (effective November 8, 2026); Medicare Coverage Database billing and coding articles: MCD release November 12, 2026 (effective November 8, 2026). Next CMS release: weekly, every Thursday.

Contractor
Novitas Solutions, Inc.
States and territories
12
AR CO DC DE LA MD MS NJ NM OK PA TX
Revision effective
2026-12-20
Original effective
2026-12-20
Policy text
764 words
Covered ICD-10 codes (articles)
3

Where this LCD applies

Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.

Contracts that apply LCD L40378
ContractContractorTypeStates
12101Novitas Solutions, Inc.A and B MACDE
12201Novitas Solutions, Inc.A and B MACDC
12301Novitas Solutions, Inc.A and B MACMD
12401Novitas Solutions, Inc.A and B MACNJ
12501Novitas Solutions, Inc.A and B MACPA
12102Novitas Solutions, Inc.A and B MACDE
12202Novitas Solutions, Inc.A and B MACDC
12302Novitas Solutions, Inc.A and B MACMD
12402Novitas Solutions, Inc.A and B MACNJ
12502Novitas Solutions, Inc.A and B MACPA
12901Novitas Solutions, Inc.A and B MACDC DE MD NJ PA
07102Novitas Solutions, Inc.A and B MACAR
07202Novitas Solutions, Inc.A and B MACLA
07101Novitas Solutions, Inc.A and B MACAR
07201Novitas Solutions, Inc.A and B MACLA
07301Novitas Solutions, Inc.A and B MACMS
07302Novitas Solutions, Inc.A and B MACMS
04111Novitas Solutions, Inc.A and B MACCO
04211Novitas Solutions, Inc.A and B MACNM
04311Novitas Solutions, Inc.A and B MACOK
04411Novitas Solutions, Inc.A and B MACTX
04112Novitas Solutions, Inc.A and B MACCO
04212Novitas Solutions, Inc.A and B MACNM
04312Novitas Solutions, Inc.A and B MACOK
04412Novitas Solutions, Inc.A and B MACTX
04911Novitas Solutions, Inc.A and B MACCO NM OK TX

Billing and coding article A60424: diagnoses and procedure codes

Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A60424 (Billing and Coding: Urine-based Biomarkers in Patients with Microhematuria) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.

Coverage is only half of the claim edit: when two of the listed procedure codes are billed on the same date, test the pair against the NCCI edits before relying on both being paid.

A60424: Billing and Coding: Urine-based Biomarkers in Patients with Microhematuria (Billing and Coding)

Covered ICD-10-CM codes
3
1 group
Non-covered ICD-10-CM codes
0
Procedure codes listed
13
Full article
cms.gov record
First 3 covered ICD-10-CM codes in A60424
ICD-10-CMDescription (FY2027)
R31.1Benign essential microscopic hematuria
R31.21Asymptomatic microscopic hematuria
R31.29Other microscopic hematuria

Procedure codes: 0363U, 0365U, 0420U, 0549U, 0613U, 81479, 81599, 84999, 86294, 86316, 86386, 88120, 88121.

Coverage indications, limitations and medical necessity

Note: Compliance with the provisions in this LCD may be monitored and addressed through post-payment data analysis and subsequent medical review audits.

Covered Indications

Urine-based biomarker tests used to aid in risk stratification of patients with MH are considered reasonable and necessary when ALL of the following conditions are met:

• The patient 1 :

• Has a clinical presentation of MH; AND

• All other potential causes have been ruled out; AND

• Does not have a current or previous diagnosis of a urothelial or other urologic malignancy; AND

• Is considered intermediate risk as defined by published guidelines; AND

• Has not received a cystoscopy for hematuria in the previous 6 months; AND

• Has been appropriately counseled and intends to forgo a cystoscopy contingent on test results; AND

• Has not been tested with the same or similar test within the previous 6 months; AND

• Falls within the intended-use population for which the test was developed and validated.

• The laboratory providing the test is responsible for clearly identifying the patient population and indication for use to treating clinicians.

• The test must demonstrate ALL of the following 1 :

• Accurate risk stratification to inform cystoscopy decision-making.

• Documentation that the test methodology and analytes have been adequately characterized to support consistent and reliable measurement in the intended‑use population.

• Documentation that establishes the clinical validity (CV) of the measured analytes in published, peer‑reviewed literature, demonstrating a clear and significant biological or molecular basis for stratifying patients and informing positive or negative clinical management decisions within a clearly defined population.

• Equivalence or superiority for sensitivity or specificity of detecting UC to other already accepted methods for the same intended-use measuring the same or comparable analytes.

Limitations

The following are considered not reasonable and necessary 1 :

• Use of UBB testing when the patient has undergone cystoscopy for hematuria within the preceding 6 months.

• Repeat use of the same or similar biomarker testing within a 6-month timeframe.

• Use of UBB testing in patients who are clinically risk‑stratified as low risk according to applicable specialty society guidelines.

• Use of UBB testing in patients who are clinically risk‑stratified as high risk according to applicable specialty society guidelines.

Provider Qualifications

Services will be considered reasonable and necessary when all aspects of care are within the scope of practice of the provider’s professional licensure, when performed according to the supervision requirements per state scope of practice laws, and when all procedures are performed by appropriately trained providers in the appropriate setting.

The following provider qualification requirements must be met for the service to be considered reasonable and necessary. The ordering provider of a UBB test for a patient with MH must:

• Be the treating clinician who is responsible for the patient; AND

• Understand how the test result will impact the patient’s condition; AND

• Have presented this information to the patient and confirmed patient understanding.

(See Code of Federal Regulations, Title 42, Volume 2, Chapter IV, Part 410.32(a))

Notice: Services performed for any given diagnosis must meet all the indications and limitations stated in this LCD, the general requirements for medical necessity as stated in CMS payment policy manuals, all existing CMS national coverage determinations, and all Medicare payment rules.

Contextual Policy Insights

Microhematuria is a common clinical finding with a wide range of potential causes, most of which are benign. Although the overall likelihood of UC is low, accurate evaluation remains important. Current professional guidelines support a risk‑stratified approach, recognizing that many patients, particularly those at low risk, may not require immediate invasive testing. Urine-based biomarkers have emerged as potential adjunctive tools to help refine risk assessment in select patients.

Because this policy addresses the use of UBBs in patients with MH, the evidence considered is focused primarily on studies conducted in MH populations. Although some published studies have evaluated UBBs in broader populations that include patients with gross hematuria (GH), important differences exist between these groups with respect to cancer prevalence, underlying etiologies, patient characteristics, and diagnostic evaluation pathways. These differences may affect the extent to which diagnostic performance estimates observed in GH populations can be applied to patients undergoing evaluation for MH. Accordingly, greater emphasis is placed on evidence derived from MH populations because it more closely reflects the intended-use population and clinical setting in which UBB-guided risk stratification would be used.

This policy provides context for the limited circumstances under which such testing may be considered reasonable and necessary under Medicare and is intended to align with contemporary evidence and guideline‑based evaluation practices.

Summary of evidence (opening)

Evidence Certainty Methodology

This contractor evaluated peer-reviewed, evidence-based literature reporting the clinical utility of UBBs in MH using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology. 2 The PICO parameters documented below were prespecified to ensure transparency and reproducibility:

Population: Patients with hematuria undergoing urologic evaluations

Intervention: Use of urine biomarkers to assess risk of underlying urinary tract malignancy

The contractor cites 65 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.

Dates, lineage and related policies

Original determination effective
2026-12-20
Current revision effective
2026-12-20
MCD version
38

Other related documents: A60570 (Response to Comments).

Using this policy on a claim

Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Novitas Solutions, Inc. hub lists every other active policy from the same contractor.

The same policy title at other contractors

Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.

For teams evaluating QuickIntell software

Where QuickIntell fits with this policy

If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions

What does LCD L40378 cover?

Urine-based biomarker tests used to aid in risk stratification of patients with MH are considered reasonable and necessary when ALL of the following conditions are met: The full 764-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.

Which states does LCD L40378 apply to?

Novitas Solutions, Inc. applies it to Medicare claims in 11 states plus DC: AR, CO, DC, DE, LA, MD, MS, NJ, NM, OK, PA, TX. It binds only that contractor; 1 other contractor version of this title governs other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.

Which diagnosis codes support medical necessity under LCD L40378?

The companion billing and coding article A60424 lists 3 ICD-10-CM codes in 1 group that support medical necessity; the first 3 appear on this page, where the complete list opens by group with the contractor's group instructions.

How do I appeal a denial under LCD L40378?

A denial under LCD L40378 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A60424's 3 covered diagnosis codes, then file a redetermination with Novitas Solutions, Inc. within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.